Aquatic Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Aquatic Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.8M	Buy	10,684 +4,309	+68%	+$639K	0.06%	399
2026 Q1	$840K	Buy	+6,375	New	+$846K	0.02%	603
2024 Q4	–	Sell	-88,900	Closed	-$10.2M	–	1524
2024 Q3	$10.2M	Buy	88,900 +64,100	+258%	+$8.79M	0.27%	99
2024 Q2	$3.41M	Buy	+24,800	New	+$3.4M	0.13%	167
2023 Q2	–	Sell	-600	Closed	-$61K	–	1613
2023 Q1	$61K	Buy	+600	New	+$62.4K	﹤0.01%	849
2022 Q4	–	Sell	-27,100	Closed	-$2.88M	–	1660
2022 Q3	$2.88M	Buy	27,100 +24,500	+942%	+$2.49M	0.28%	89
2022 Q2	$253K	Buy	+2,600	New	+$240K	0.08%	284

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Aquatic Capital Management's NBIX Position: Q2 2026 in Review

Aquatic Capital Management increased its Neurocrine Biosciences (NBIX) stake by 68% in Q2 2026, buying an estimated $639K and bringing the position to 10,684 shares worth $1.8M. The position accounts for 0.06% of the portfolio, ranked #399.

Aquatic Capital Management first reported a position in NBIX in Q2 2022 and has held it in 7 quarters since. The position peaked at $10.2M in Q3 2024. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Aquatic Capital Management held 10,684 shares of Neurocrine Biosciences worth $1.8M as of Q2 2026.
Aquatic Capital Management bought 4,309 Neurocrine Biosciences shares in Q2 2026, an estimated $639K.
Neurocrine Biosciences made up 0.06% of Aquatic Capital Management's portfolio in Q2 2026, its #399 holding.
Aquatic Capital Management first reported a position in Neurocrine Biosciences in Q2 2022 and has held it in 7 quarters since.
Aquatic Capital Management's Neurocrine Biosciences position peaked at $10.2M in Q3 2024.
772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.